Your browser doesn't support javascript.
loading
Non-Thermal Plasma-Induced Immunogenic Cell Death in Cancer: A Topical Review.
Khalili, Marian; Daniels, Lynsey; Lin, Abraham; Krebs, Fred C; Snook, Adam E; Bekeschus, Sander; Bowne, Wilbur B; Miller, Vandana.
Affiliation
  • Khalili M; Division of Surgery Oncology, Department of Surgery, Drexel University College of Medicine, Philadelphia, PA.
  • Daniels L; Division of Surgery Oncology, Department of Surgery, Drexel University College of Medicine, Philadelphia, PA.
  • Lin A; Plasma, Laser Ablation, and Surface Modeling (PLASMANT) Group, Department of Chemistry, University of Antwerp.
  • Krebs FC; Center for Oncological Research (CORE), University of Antwerp.
  • Snook AE; Department of Microbiology and Immunology, and Institute for Molecular Medicine &. Infectious Disease, Drexel University College of Medicine, Philadelphia, PA.
  • Bekeschus S; Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
  • Bowne WB; Centre for Innovation Competence (ZIK) plasmatis, Leibniz Institute for Plasma Science and Technology (INP Greifswald), Felix-Hausdorff-Str.2, 17489 Greifswald, Germany.
  • Miller V; Division of Surgery Oncology, Department of Surgery, Drexel University College of Medicine, Philadelphia, PA.
J Phys D Appl Phys ; 52(42)2019 Oct 22.
Article in En | MEDLINE | ID: mdl-31485083
ABSTRACT
Recent advances in biomedical research in cancer immunotherapy have identified the use of an oxidative stress-based approach to treat cancers, which works by inducing immunogenic cell death (ICD) in cancer cells. Since the anti-cancer effects of non-thermal plasma (NTP) are largely attributed to the reactive oxygen and nitrogen species that are delivered to and generated inside the target cancer cells, it is reasonable to postulate that NTP would be an effective modality for ICD induction. NTP treatment of tumors has been shown to destroy cancer cells rapidly and, under specific treatment regimens, this leads to systemic tumor-specific immunity. The translational benefit of NTP for treatment of cancer relies on its ability to enhance the interactions between NTP-exposed tumor cells and local immune cells which initiates subsequent protective immune responses. This review discusses results from recent investigations of NTP application to induce immunogenic cell death in cancer cells. With further optimization of clinical devices and treatment protocols, NTP can become an essential part of the therapeutic armament against cancer.

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: J Phys D Appl Phys Year: 2019 Type: Article Affiliation country: Panama

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: J Phys D Appl Phys Year: 2019 Type: Article Affiliation country: Panama